Good news! Our "Antibody Drug New Concentration Technology R&D Team" has been selected as the seventh batch of high-level talent introduction teams in Quanzhou City

On December 24th, the Science and Technology Bureau of Quanzhou City announced the selection list of the seventh batch of high-level talent teams introduced by Quanzhou City under the Quanzhou Talent "Harbor Plan". Our company's "Antibody Drug New Concentration Technology Research and Development Team" led by Dr. Huang Zhijian was successfully selected.

热烈祝贺

喜报频传创佳绩 扬帆启航祝未来

New concentration technology research and development team for antibody drugs

Project Introduction

Project background
With the incidence rate of severe diseases and malignant tumors rising year by year, human health is facing unprecedented challenges. As an important means of addressing these diseases, antibody drugs have achieved rapid development in recent years, with a compound annual growth rate of up to 40% in the domestic market. However, the concentration step is crucial in the production process of antibody drugs, and the existing ultrafiltration technology has pain points such as long operation time, easy membrane blockage, and high cost, which seriously affect the preparation efficiency and cost of antibody drugs.

Technological innovation
It is in this context that Dr. Huang Zhijian's research and development team for a new concentration technology for antibody drugs, led by Dr. Huang Zhijian, has developed a brand new concentration patent technology with exclusive technical advantages. This technology can perfectly solve all the pain points of ultrafiltration technology, with significant advantages such as low cost, high efficiency, low loss and zero deactivation of drug molecules after concentration. This breakthrough innovation not only reduces the concentration cost in the preparation of biomacromolecule drugs, but also eliminates the risk of drug molecule inactivation after concentration, bringing revolutionary changes to the production of antibody drugs.

Industry prospect
With the booming development of the antibody drug industry, the market prospects for this technology are also very broad. It can replace existing ultrafiltration technology and become the new favorite of the antibody drug production industry, significantly reducing the research and development costs and production concentration costs of antibody drugs, thereby reducing the cost of medication for the public and allowing more people to enjoy high-quality antibody drug treatment.
More importantly, this technology can also help hospitals, testing institutions, and households achieve a significant increase in medical diagnostic sensitivity, thereby achieving the goal of early disease detection or cancer screening, helping to improve public health, reduce the occurrence and spread of diseases, and lower medical costs.

Industry driven
I believe that the promotion and application of this technology will drive the development of the entire antibody drug research and production industry, and with the influx of more talents and capital, the antibody drug research and production industry will usher in greater development opportunities.

We also look forward to attracting more antibody drug R&D and production enterprises to settle in Quanzhou with the support of various levels of government and relevant departments in Quanzhou, and jointly promoting the high-quality development of the antibody drug R&D and production industry in Fujian Province and even the entire South China region!